Recursion Pharmaceuticals (RXRX) Cash & Current Investments (2020 - 2026)

Recursion Pharmaceuticals has reported Cash & Current Investments for 7 years, with the latest figure at $660.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 31.07% year-over-year to $660.0 million; the trailing twelve-month figure through Mar 2026 stood at $660.0 million (up 31.07% YoY), and the FY2025 full-year result was $747.9 million, up 25.19% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $660.0 million, down from $747.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $747.9 million in Q4 2025, with the low at $299.5 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $502.7 million across 5 years, with a median of $476.1 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 132.47% — and 2024, when it slumped 36.87%.
• Recursion Pharmaceuticals' Cash & Current Investments stood at $551.2 million in 2022, then dropped by 28.37% to $394.8 million in 2023, then jumped by 51.32% to $597.4 million in 2024, then advanced by 25.19% to $747.9 million in 2025, then retreated by 11.75% to $660.0 million in 2026.
• The last three Cash & Current Investments figures came in at $660.0 million (Q1 2026), $747.9 million (Q4 2025), and $663.0 million (Q3 2025), per Business Quant data.